NCT00742495 2012-10-24
BCX1777-108
Mundipharma Research Limited
Phase 1/2 Terminated
Clinical Trials
7 trialsNCT00289549 2012-02-08
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
BioCryst Pharmaceuticals
Phase 2 Completed
NCT00501735 2012-01-23
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
BioCryst Pharmaceuticals
Phase 2 Completed
NCT00289562 2012-01-20
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
BioCryst Pharmaceuticals
Phase 1/2 Completed
NCT00095381 2012-01-19
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
BioCryst Pharmaceuticals
Phase 2 Completed
NCT00646165 2010-03-31
Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia
Mundipharma Research Limited
Phase 1 Terminated
NCT00035022 2006-01-13
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
BioCryst Pharmaceuticals
Phase 1/2 Completed